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Introduction 
Although a number of professional organisations recommend the routine screening of 
cancer patients for emotional distress, in many centres this is infrequently conducted 
because they lack suitable psychosocial interventions to offer distressed patients.1-5 It 
is therefore essential to improve the evidence base around specific and effective 
interventions that can later be incorporated into routine cancer care. To provide 
sufficiently rigorous data supporting the benefit of any survivorship intervention, 
studies should be sized to allow adequate statistical powering and employ 
methodologies such as randomisation. Unfortunately, the majority of 
psychosocial/survivorship intervention studies do not adopt these methodologies due 
to challenges in funding and recruitment.5-7  
 
Arguably, the best utilisation of randomised clinical studies occurs in clinical drug 
development whereby results from at least one Phase III drug development trial 
(P3DDT) are required for the licensing and approval of any new pharmaceutical 
agent.8 Important components of any P3DDT include defining the criteria (such as 
clinical characteristics and biomarkers) to select suitable patients, deciding the dose 
and duration of the investigational agent to be tested, developing a randomisation 
scheme and suitable control arm, designing end-points and incorporating safety 
reporting.9 These elements of a P3DDT are usually informed by preceding Phase I 
and II trials, appropriate theoretical modelling and pilot/feasibility studies.10 To 
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explore whether P3DDT methodology could be translated to the design of a 
survivorship study, we incorporated it in the development of the OVPSYCH trial, to 
evaluate the impact of a psychosocial support intervention in patients with ovarian 
cancer (OC). The hypothesis of OVPSYCH was that post-chemotherapy psychosocial 
support improves the psychological and overall wellbeing of OC patients. We first 
conducted the pilot, OVPSYCH1, to which we recruited 32 patients. OVPSYCH1 was 
approved by Bradford Research Ethics Committee in 2011 (ref 11/YH/0117). Our 
findings from this pilot informed the design of OVPSYCH2, the first randomised 
study of post-chemotherapy psychosocial support to be conducted in UK ovarian 
cancer patients. The overall design of the OVSYCH studies is summarised in figure 1.  
 
Below we outline some of the key features of P3DDT methodology that were adapted 
for OVPSYCH. 
 
1. Using Biomarkers for Patient Selection 
P3DDTs, where possible, use a biomarker to select or enrich for patients most likely 
to benefit from the study intervention. An example is Phase III lung cancer trials 
where only patients with tumour EGFR mutations were randomised for EGFR-
targeted therapy11. In OVPSYCH, we decided to screen OC patients for psychosocial 
morbidity, randomising only those who scored over a defined threshold. Screening 
options included using a Distress Thermometer12 or Cancer Worry Scale13 but, as we 
could not predict whether depression or anxiety would predominate in our study 
patients, we chose to screen for both using the Patient Health Questionnaire-9 (PHQ-
9) depression and Generalized Anxiety Disorder (GAD-7) questionnaires. These 
questionnaires have been demonstrated to be sensitive and reliable tools for cancer 
survivorship14,15. Patients also completed EORTC QLQ-C30 and OV28 
questionnaires so that any depression/anxiety scores could be correlated with general 
Quality of Life (QOL) measures. 
 
The PHQ-9 and GAD-7 scores were developed by psychiatrists to screen and detect 
depression and anxiety respectively; scores on either scale of  4 indicate no 
symptoms, whereas scores 5-9 indicate mild and 10-14 moderate depression/anxiety. 
For the GAD-7 scale, scores above 15 (of a 21-score maximum) represent severe 
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anxiety. For the PHQ-9 scale, a score from 15-19 represents moderately severe 
depression but scores 20 (of a 27-score maximum) indicate severe depression with 
an affirmative answer to question 9 signalling suicidal intent.16,17 Based on a previous 
study where 60% OC patients reported moderate or severe psychological symptoms 
using EORTC QLQ-C30 and Q28 scores,18 we initially aimed to recruit only patients 
with moderate or severe anxiety or depression: with PHQ-9 and/or a GAD-7 scores 
10. However, during the pilot we discovered that, once precise symptom-specific 
questionnaires were implemented, depression/anxiety was lower than expected with 
only one third of patients reporting PHQ-9 scores 10. We therefore adapted the cut-
off to include patients with mild, moderate or moderately-severe depression, 
corresponding to a PHQ-9 score 4. In these patients, GAD-7 scores were generally 
also elevated, but none had positive GAD-7 and negative PHQ-9 measures. We 
concluded that, in our pilot study, the PHQ-9 was a better stratifier of emotional 
distress than GAD-7.  
 
Unlike in a P3DDT where patients with highest levels of a biomarker have greatest 
theoretical likelihood of response to the study intervention, in OVPSYCH those with 
the highest “biomarker scores” such as PHQ-9 scores ≥20 (denoting severe 
depression) or those that ticked question 9 of the PHQ-9 scale were at highest risk of 
self-harm. As these patients would be expected to enter a randomisation process that 
could result in them being assigned a “non-intervention” arm, we mandated in the 
protocol that these patients were removed from the study and immediately referred for 
psychiatric or psychological support.  
 
In identifying a patient stratification marker, in this case PHQ-9, we found that 
symptom-specific, quantitative questionnaires provided the best means of selecting 
patients. However, using these more discriminatory tools yielded a lower than 
expected number of eligible patients compared to less specific QOL scores. We 
concluded that eligibility range must be carefully defined and, ideally, previously 
validated in a similar patient population. Unlike P3DDTs, in survivorship studies, 
patients who have very high scores in symptom-specific questionnaires may be unsafe 
for randomisation. In this situation, an appropriate treatment plan should be in place 
for those scoring over the upper safe limit.  
   




2. Ensuring a valid control group  
 
In P3DDTs, patients are usually randomised to either the intervention or control arm. 
Controls receive a placebo (in a blinded study) or an equivalent active/ standard of 
care treatment. In the context of a survivorship study, designing a control arm can be 
challenging. As those in the intervention arm of OVPSYCH were requested to come 
into the hospital for additional counselling sessions, it would have been unethical to 
expect control patients to attend hospital for an equivalent number of visits but 
receive no counselling (placebo).  But equally, there is insufficient evidence for the 
effectiveness of any specific type of psychosocial therapy to offer as an “equivalent 
active” control. We selected baseline service provision as the control against which 
the intervention arm could be compared. However, as there is no UK standard 
survivorship provision, this could vary between centres. As OVPSYCH1 was piloted 
in a single centre, we defined the activities in the control arm as “referral for 
survivorship support on demand or if expressing symptoms of concern”.  
 
Once randomisation was in place, we observed another bias that has also been 
described in P3DDTs.19 Patients who agreed to enter OVPSYCH1 were generally 
more open to discussion about their psychological welfare and sought other means of 
support if they were randomised to the non-intervention arm. We therefore introduced 
an “other treatments” form so trials staff could document any changes to medications 
or commencement of other supportive therapies (such as counselling or anti-
depressants) during the study period. Data from these forms was to be included in the 
statistical analysis at study closure.  
 
In all randomised studies, control patients may be motivated to seek a similar 
intervention to those in the investigative study arm. This is easier for patients to 
achieve in a survivorship study than in a trial of a novel investigational agent. We 
recommend that survivorship studies are powered to allow some contamination and 
that patients are encouraged to disclose “other treatments” during their study follow 
up. In addition, trials may benefit from measuring access and treatment requirements 
from an equivalent, non-trial group prior to the start of recruitment to provide a 
reliable comparator. This could, for example, be achieved by referencing an 
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observational study documenting the uptake of supportive interventions in a similar 
patient population. 
 
3. Providing Safety Measures  
 
P3DDTs include harm-related data reporting.20 Among other requirements, such as 
informing patients of possible risks of an intervention, study sites are required to 
submit timely Adverse Event (AE) Reports to the sponsors if study-related side-
effects occur. Events such as admissions to hospital for worsening depression or death 
due to suicide are not inconceivable in cancer patients and it is possible that the trial 
intervention (cognitive behavioural therapy (CBT)-based counselling in OVPSYCH) 
is unsuitable for or may exacerbate the psychological concerns of patients.21 We 
therefore included an Adverse Event Reporting system within OVPSYCH so that any 
AEs would be noted and that suitable actions to be taken to participants if AEs were 
caused by the study intervention. Along with a robust AE reporting system, a Trial 
Management Group (TMG) should be convened to periodically review adverse events 
and provide an additional layer of oversight to protect participants and investigators. 
If necessary, the TMG should have the power to decide early termination of the trial 
on safety grounds.  
 
Rather than being merely procedural, it is important to include an AE reporting 
system when designing a randomised survivorship trial. A TMG is also necessary to 
provide oversight and ensure intervention-related AEs are followed with suitable 
protective actions to participants. Not only does this ensure the safety of study 
participants and the integrity of investigators but also provides important information 
that will be applicable to the later adoption of an intervention into clinical practice.   
 
4. Defining study endpoints 
 
Fundamental to clinical studies are their primary and secondary endpoints and the 
metrics used to assess them. The most commonly chosen primary endpoints for 
P3DDTs are progression-free (PFS) and overall survival (OS); whereas patient 
experience is often chosen as a secondary endpoint and assessed using QOL 
questionnaires.  In survivorship studies, the emphasis is reversed with primary 
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endpoints being QOL or symptom-specific measures. Although PFS and OS are valid 
secondary endpoints in survivorship studies, particularly as psychological wellbeing 
has been shown to contribute to lifespan,22 long-term follow-up of patients to gather 
their survival data has cost implications. For this reason, and because we predicted 
that survival was unlikely to have been impacted by our intervention, we did not 
collect survival data in OVPSYCH and chose to set a change in PHQ-9 as our primary 
endpoint.   
 
As there are conflicting data from small longitudinal studies exploring the QOL 
trajectory in OC patients after chemotherapy, we predicted that psychosocial scores 
would deteriorate during chemotherapy treatment and remain poor in the following 
months.23,24 To statistically power OVPSYCH, we predicted the PHQ-9 score would 
be elevated immediately after chemotherapy in both arms but fall to a lower level in 
the intervention arm. We then considered the time required to capture our endpoint. 
Questionnaire-based trials often show a drop-off in completion rates over time. As 
follow-up visits were 3 monthly for 2 years, we predicted poor questionnaire return 
and chose to measure data at the earliest (3 month) timepoint for our primary 
endpoint, and defined significance as a ≥5 change (from baseline) in mean PHQ-9 
score in the intervention compared to the control arm. Secondary analyses include 
comparisons of PHQ-9 and between-group comparisons using the other scores (GAD-
7, EORTC QLQ-OV28 and QLQ-C30) at later time points. However, we recognised 
that lack of questionnaire return may result in these secondary endpoints being unmet.  
 
We conclude that, unlike in P3DDTs, QOL studies need to assume poor questionnaire 
compliance and focus their primary endpoints around early timepoints. If funding is 
limited, endpoint measures should be directly appropriate to the intervention aims 
rather than focusing on biological progression or survival. However, if longer-term 
follow-up data is essential, investigators could consider direct methods of follow-up 
with participants, such as by telephone, to circumnavigate institutional limitations 
such as apathy in collecting questionnaires from participants. 
 
 
5. Defining and standardising the intervention: 
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An important component in a P3DDT is ensuring the intervention is standardised, in 
the case of trial of a therapeutic agent, in dose and schedule. We initially intended that 
the intervention, a course of CBT-based psychosocial support sessions, was provided 
by the hospital-based survivorship service. However, this service is non-standardised 
across the UK and is provided by counsellors, psychologists or psychiatrists and with 
different approaches (such as anti-depressants, CBT, mindfulness etc), in individual 
sessions or in groups.  
 
In the pilot study, we opted for a standard “dose” of three 90-minute sessions of CBT-
based counselling, to be provided in the three months between the first and second 
follow-up visit. So as not to interfere with daily outpatient activities, patients were 
invited to early-evening appointments with the departmental counsellor in the 
chemotherapy unit. Although the session content was not strictly predefined, it was 
designed to cover a number of specific topics such as how to manage anxiety, stress, 
depression and anger, and included broader well-being issues such as relationships, 
diet and ways to manage day-to-day living. However, amongst those randomised to 
receive the intervention, attendance was poor. Qualitative feedback indicated that 
patients were reluctant to return to the place where they had received chemotherapy 
and the early-evening timing of the sessions was also unpopular, particularly for those 
experiencing post-chemotherapy fatigue.  
 
We concluded that the venue for a psychosocial intervention is vital, the intervention 
should be conducted at a time that suits the patients and at a location that does not 
have negative associations. As there is considerable variability in experience and 
training of those providing survivorship support in cancer hospitals, we realised that 
the standardisation of any psychosocial intervention would be challenging, both 
between participants within one centre and across multiple centres. We therefore 
sought a tertiary, independent care centre (Maggie’s Cancer Centres) to provide a 
standardised psychosocial intervention for our main OVPSYCH study.  In our pilot, 
treatment fidelity was poor. We therefore propose that for psychosocial intervention 
studies, a register of attendance should be maintained by those providing the 
intervention, in this case  the Maggie’s psychologists, and that this is included in any 
data collection on study completion. Moreover, poor compliance should be predicted 
to prevent statistical underpowering.  
   




In order to improve the quality of survivorship support available to cancer patients, 
studies must provide a robust evidence-base for interventions that can be adopted into 
clinical practice.6 We have shown here that applying methodology developed for 
P3DDTs is useful in terms of: randomisation strategies, adverse event reporting, 
patient stratification and the selection and standardisation of study arms. However, 
there are several important limitations. P3DDTs include long-term survival data as 
primary endpoints but, in survivorship trials where funding is invariably limited, 
short-term primary endpoints are preferred to accommodate diminishing questionnaire 
return and to limit the expense of patient follow-up. Thus survivorship studies, even 
when randomised, may fail to give a true reflection of the impact of an intervention on 
the longer-term psychological morbidity and survival of study patients. Institutional 
apathy is a recurrent limitation to conducting survivorship research and the onus to 
participate and complete information sheets can fall on the participants themselves. It 
is therefore vital that any proposed intervention is fully acceptable to participants to 
ensure their motivation and compliance.   
 
Uncertainties around the natural psychosocial trajectory after cancer treatment along 
with limited standardised survivorship provision in cancer centres creates an 
unreliable baseline against which novel interventions must be compared. With the 
emergence of P3DDTs evaluating maintenance therapies in the OC setting and 
publishing their QOL data alongside the main trial results, our understanding of the 
long-term QOL trajectory in OC patients is improving. However, these patients are 
preselected by performance status and other (e.g. biochemical) parameters and are not 
necessarily representative of those seen in standard of care settings. These data should 
be interpreted with caution when designing psychosocial intervention studies.   
 
As cancer survival improves and greater numbers of patients require evidence-based 
psychosocial support, the need for good quality survivorship research will intensify. 
Survivorship studies are challenging to conduct for a number of well-documented 
reasons, including cost limitations and lack of institutional interest or support.12,25 This 
creates a chicken-and-egg situation whereby there is an insufficient evidence-base 
from which to implement standardised survivorship programmes in cancer centres. In 
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the context of cancer distress, this can lead to long-term psychological morbidity in 
patients, resulting in failure to return to work and chronic demands on healthcare 
resources.26 In an attempt to break this cycle, we applied P3DDT methodology to the 
design of a survivorship intervention study, OVPSYCH2. Here we described the pilot 
study OVPSYCH1, conducted to determine the limitations of this approach. These 
findings were subsequently incorporated into the design of the main OVPSYCH2 
trial, a multi-centred randomised study of a psychosocial supportive intervention for 
OC patients following chemotherapy.  
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Figure 1: OVPSYCH Trial Design 
OVPSYCH is a randomised controlled study to assess the impact of a psychosocial 
intervention following chemotherapy for advanced or recurrent ovarian cancer. 
Potentially eligible patients were provided with study information at their final 
chemotherapy session (of their chemotherapy course for newly diagnosed or relapsed 
OC). They were then invited to consent at their first follow-up visit, approximately 4-
6 weeks later and completed questionnaires to confirm their eligibility. Those scoring 
about a threshold on PHQ-9 and/or GAD-7 questionnaires were randomised 1:1 to the 
intervention or standard of care. Those in the intervention group were invited to 
receive 3 sessions of psychological support during the next 3 months. Those in the 
control arm received standard of care, and were only referred for specialist supportive 
care services (but not the OVPSYCH intervention) if they requested it or had 
symptoms of concern. Patients in both study arms then attended for routine outpatient 
follow up, every 3 months for up to 2 years. At each of these appointments, patients 
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were invited to complete QOL, PHQ-9 and GAD-7 questionnaires. This trial design 
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